Classifications within Molecular Subtypes Enables Identification of BRCA1/BRCA2 Mutation Carriers by RNA Tumor Profiling
暂无分享,去创建一个
Mads Thomassen | Torben A. Kruse | Qihua Tan | Martin J. Larsen | M. Larsen | A. Lykkesfeldt | A. Gerdes | M. Bak | Q. Tan | M. Thomassen | B. Ejlertsen | T. Kruse | T. V. Hansen | Anne-Vibeke Lænkholm | A. Lænkholm | K. Sørensen | Martin Bak | Anne E. Lykkesfeldt | Bent Ejlertsen | Anne-Marie Gerdes | Kristina P. Sørensen | Thomas v. O. Hansen
[1] J. Peterse,et al. Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH , 2008, Breast Cancer Research and Treatment.
[2] M. J. van de Vijver,et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Gerdes,et al. Evaluation of two different models to predict BRCA1 and BRCA2 mutations in a cohort of Danish hereditary breast and/or ovarian cancer families , 2006, Clinical genetics.
[4] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[5] D. Sgroi,et al. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features , 2010, Breast Cancer Research.
[6] S. Dudoit,et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. , 2002, Nucleic acids research.
[7] Elmar Bucher,et al. Genome‐wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients , 2008, Genes, chromosomes & cancer.
[8] S. Powell,et al. BRCA1 and BRCA2: different roles in a common pathway of genome protection , 2011, Nature Reviews Cancer.
[9] J. Dungan. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .
[10] A. Ashworth,et al. Profiling familial breast cancer , 2001, Nature Medicine.
[11] J. Foekens,et al. Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes , 2012, Breast Cancer Research and Treatment.
[12] M. Ringnér,et al. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics , 2010, Breast Cancer Research.
[13] J. Benítez,et al. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: A high proportion of mutations unique to Spain and evidence of founder effects , 2003, Human mutation.
[14] A. Børresen-Dale,et al. COMPLEX LANDSCAPES OF SOMATIC REARRANGEMENT IN HUMAN BREAST CANCER GENOMES , 2009, Nature.
[15] Stephen Fox,et al. Subtypes of familial breast tumours revealed by expression and copy number profiling , 2010, Breast Cancer Research and Treatment.
[16] M. Stratton. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases , 1997, The Lancet.
[17] F. Fostira,et al. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study , 2012, Breast Cancer Research and Treatment.
[18] P. Pharoah,et al. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases , 2000, British Journal of Cancer.
[19] Mark Robson,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.
[20] K. A. Gelmon. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .
[21] Giovanni Parmigiani,et al. Meta-analysis of BRCA1 and BRCA2 penetrance. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] P. Devilee,et al. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH , 2012, Breast Cancer Research and Treatment.
[23] Tara L. Naylor,et al. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. , 2005, Cancer research.
[24] Robert Tibshirani,et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer , 2006, Genes, chromosomes & cancer.
[25] G E Tomlinson,et al. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. , 1999, Cancer research.
[26] J. Oosterwijk,et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age , 2010, Breast Cancer Research and Treatment.
[27] B. Carter. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) , 2013 .
[28] K. Brusgaard,et al. Spotting and validation of a genome wide oligonucleotide chip with duplicate measurement of each gene. , 2006, Biochemical and biophysical research communications.
[29] William D. Foulkes,et al. Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .
[30] M. Dąbrowska,et al. Limited significance of family history for presence of BRCA1 gene mutation in Polish breast and ovarian cancer cases , 2012, Familial Cancer.
[31] K Miller,et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] L. Bégin,et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.
[33] Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases , 2000 .
[34] Julian Peto,et al. Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.
[35] Mads Thomassen,et al. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 , 2011, Breast Cancer Research.
[36] A. Nobel,et al. The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.
[37] S. Rodenhuis,et al. Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness , 2011, Breast Cancer Research.
[38] C. Wang,et al. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. , 1999, Science.
[39] M. Ringnér,et al. Molecular and Cellular Pathobiology The Retinoblastoma Gene Undergoes Rearrangements in BRCA 1-De fi cient Basal-like Breast Cancer , 2012 .
[40] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] S. Lakhani,et al. Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic? , 2010, Breast Cancer Research.
[42] E. Dougherty,et al. Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.
[43] Giske Ursin,et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. , 2006, Cancer research.
[44] Christopher I Amos,et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] J. Lubiński,et al. BRCA1-related gene signature in breast cancer: the role of ER status and molecular type. , 2011, Frontiers in bioscience.
[46] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[47] A. Jemal,et al. Global Cancer Statistics , 2011 .
[48] Yee Hwa Yang,et al. Normalization for two-color cDNA microarray data , 2003 .
[49] G. Casey,et al. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[50] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[51] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[52] N. Sneige,et al. Triple Negative Breast Carcinoma and the Basal Phenotype: From Expression Profiling to Clinical Practice , 2007, Advances in anatomic pathology.
[53] A. Reith. Genes, Chromosomes and Cancer , 2004, Cellular Oncology : the Official Journal of the International Society for Cellular Oncology.
[54] O. Olopade,et al. Estrogen Receptor Status in BRCA1- and BRCA2-Related Breast Cancer , 2004, Clinical Cancer Research.
[55] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.